Neuromyelitis optica

被引:70
作者
Wingerchuk D.M. [1 ]
Weinshenker B.G. [1 ]
机构
[1] Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259
关键词
Multiple Sclerosis; Mycophenolate Mofetil; Optic Neuritis; Main Side Effect; Main Drug Interaction;
D O I
10.1007/s11940-005-0010-6
中图分类号
学科分类号
摘要
Neuromyelitis optica (Devic's syndrome) is an uncommon, idiopathic, demyelinating syndrome of the central nervous system that preferentially affects the optic nerves and spinal cord. It frequently is misdiagnosed as severe multiple sclerosis, but usually is readily distinguished from multiple sclerosis in fully developed cases because of its severity, typical magnetic resonance imaging (MRI) findings (normal brain MRI; longitudinally extensive Lesions on spinal cord MRI), and cerebrospinal fluid analysis (polymorphonuclear pleocytosis and absence of oligoclonal banding). A serum autoantibody marker, NMO-IgG, is highly specific for the disorder. Most patients have relapsing disease, and natural history studies confirm early and severe disability. We treat acute myelitis and optic neuritis exacerbations with parenteral corticosteroids and use rescue plasmapheresis for severe, refractory attacks. Immunomodulatory drugs used for typical multiple sclerosis seem ineffective for relapse prevention. We recommend systemic immunosuppression, usually with azathioprine and oral corticosteroids, for most patients. Fulminant disease and breakthrough disease may respond to other forms of humoral immunotherapy such as rituximab. Copyright © 2005 by Current Science Inc.
引用
收藏
页码:173 / 182
页数:9
相关论文
共 31 条
[1]  
Wingerchuk D.M., Hogancamp W.F., O'Brien P.C., Weinshenker B.G., The clinical course of neuromyelitis optica (Devic's syndrome), Neurology, 53, pp. 1107-1114, (1999)
[2]  
Cree B.A., Goodin D.S., Hauser S.L., Neuromyelitis optica, Semin. Neurol., 22, pp. 105-122, (2002)
[3]  
Mandler R.N., Davis L.E., Jeffery D.R., Kornfeld M., Devic's neuromyelitis optica: A clinicopathological study of 8 patients, Ann. Neurol., 34, pp. 162-168, (1993)
[4]  
O'Riordan J.I., Gallagher H.L., Thompson A.J., Et al., Clinical, CSF, and MRI findings in Devic's neuromyelitis optica, J. Neurol. Neurosurg. Psychiatry, 60, pp. 382-387, (1996)
[5]  
Weinshenker B.G., Neuromyelitis optica: What it is and what it might be, Lancet, 361, pp. 889-890, (2003)
[6]  
Wingerchuk D.M., Neuromyelitis optica: Current concepts, Front. Biosci., 9, pp. 834-840, (2004)
[7]  
Lennon V.A., Wingerchuk D.M., Kryzer T.J., Et al., A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis, Lancet, 364, pp. 2106-2112, (2004)
[8]  
Kira J., Multiple sclerosis in the Japanese population, Lancet Neurology, 2, pp. 117-127, (2003)
[9]  
Lucchinetti C.F., Mandler R.N., McGavern D., Et al., A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica, Brain, 125, pp. 1450-1461, (2002)
[10]  
Wingerchuk D.M., Weinshenker B.G., Neuromyelitis optica: Clinical predictors of a relapsing course and survival, Neurology, 60, pp. 848-853, (2003)